Kent Lake Capital LLC Grows Holdings in biote Corp. (NASDAQ:BTMD)

Kent Lake Capital LLC increased its position in shares of biote Corp. (NASDAQ:BTMDFree Report) by 0.8% during the 3rd quarter, Holdings Channel reports. The firm owned 1,284,297 shares of the company’s stock after purchasing an additional 10,596 shares during the quarter. biote makes up approximately 2.5% of Kent Lake Capital LLC’s holdings, making the stock its 17th largest holding. Kent Lake Capital LLC’s holdings in biote were worth $6,576,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC raised its position in shares of biote by 1,428.3% in the third quarter. Tower Research Capital LLC TRC now owns 5,624 shares of the company’s stock valued at $29,000 after purchasing an additional 5,256 shares during the period. California State Teachers Retirement System purchased a new stake in shares of biote in the 2nd quarter valued at $31,000. Wells Fargo & Company MN boosted its stake in shares of biote by 9,887.5% in the 2nd quarter. Wells Fargo & Company MN now owns 5,593 shares of the company’s stock valued at $38,000 after purchasing an additional 5,537 shares in the last quarter. Creative Planning purchased a new stake in biote during the 2nd quarter valued at $44,000. Finally, American International Group Inc. bought a new position in biote in the 2nd quarter worth $46,000. 22.97% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have weighed in on BTMD shares. Truist Financial reduced their price objective on shares of biote from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Thursday, January 18th. Roth Mkm dropped their price target on shares of biote from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Thursday, January 18th. B. Riley began coverage on shares of biote in a research report on Tuesday, February 20th. They issued a “buy” rating and a $9.00 price target for the company. Finally, Jefferies Financial Group began coverage on shares of biote in a report on Thursday, February 1st. They issued a “buy” rating and a $6.55 target price on the stock. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, biote currently has a consensus rating of “Buy” and an average price target of $7.71.

View Our Latest Stock Analysis on biote

biote Price Performance

biote stock traded down $0.33 during mid-day trading on Monday, reaching $5.51. 117,710 shares of the company’s stock traded hands, compared to its average volume of 97,569. The stock has a 50 day moving average of $4.62 and a two-hundred day moving average of $4.95. biote Corp. has a 12-month low of $3.65 and a 12-month high of $8.22.

About biote

(Free Report)

biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements.

Recommended Stories

Want to see what other hedge funds are holding BTMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for biote Corp. (NASDAQ:BTMDFree Report).

Institutional Ownership by Quarter for biote (NASDAQ:BTMD)

Receive News & Ratings for biote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biote and related companies with MarketBeat.com's FREE daily email newsletter.